Armata pharmaceuticals, inc. (APHB)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities:
Net loss

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

0

0

-12,593

-

-17,953

-15,961

-12,726

-12,838

-19,986

-21,582

-18,972

-18,838

-11,569

-3,755

10,865

-516

1,051

16,819

19,923

23,109

24,231

-45,729

-74,245

-64,583

0

0

0

Adjustments required to reconcile net loss to net cash used in operating activities:
Change in fair value of Series B preferred stock derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Warrants and other allocable expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Amortization of note discount and patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Warrants issued as investment fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Depreciation

1,546

1,351

1,261

1,232

1,362

1,351

1,227

975

347

343

348

350

350

338

327

340

314

299

285

158

167

127

75

123

79

82

0

0

0

Stock-based compensation

5,216

4,271

3,223

732

23

46

179

269

651

700

865

1,101

1,350

1,995

1,928

1,742

1,247

483

314

412

593

775

945

947

1,517

1,437

0

0

0

Warrants issued to placement agents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Amortization of patents

-

-

-

-

31

-

-

-

31

31

31

31

31

31

31

31

31

31

31

31

31

31

0

0

0

-

-

-

-

Charge for common stock issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,000

0

0

0

Non-cash interest expense

0

-

-

-

-

-

-

-

-

22

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

1,117

3,082

2,976

1,792

1,724

0

0

0

-

4,132

5,201

3,246

4,538

3,039

9,745

16,036

9,940

37,278

29,937

41,302

37,219

12,265

-34,512

-58,190

-49,330

0

0

0

Changes in operating assets and liabilities:
Award receivable

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash adjustments, net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16

18

14

25

13

-136

-12

92

-121

-4

1

-15

0

0

0

Tax refund

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-618

0

0

0

Accounts payable and accrued liabilities

-2,022

-1,374

-1,542

-322

658

144

272

-959

-368

-838

-405

-115

-632

406

103

204

225

-123

-683

-121

546

-977

602

-101

-531

454

0

0

0

Accrued compensation

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and lease liabilities, net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred award liability

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

-

-

-

-

0

-

-

-

0

-

-

-

-

-

204

234

53

172

0

0

0

-

-

-

0

-

-

-

-

Prepaid expenses and other current assets

-424

-348

181

483

209

337

-54

-118

221

-381

-666

-654

-610

-247

-215

63

153

182

337

-13

68

42

147

291

-22

149

0

0

0

Net cash used in operating activities

-17,194

-15,582

-16,048

-13,501

-9,711

-10,627

-9,801

-8,374

-9,429

-9,192

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest on loan notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

233

0

0

0

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,425

-10,791

-10,561

-9,781

-10,664

-10,794

-11,186

-12,572

-10,784

-10,651

-8,864

-6,292

0

0

0

Investing activities:
Purchases of property and equipment

321

224

0

0

0

-

-

-

-

58

53

49

172

279

316

403

287

210

165

186

1,008

1,202

1,202

1,097

331

102

0

0

0

Net cash used in investing activities

2,780

2,877

0

0

0

-

-

-

-

-58

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-316

-403

-287

-210

-165

-186

-1,008

-1,202

-1,202

-1,097

-331

-102

0

0

0

Financing activities:
Payment of deferred consideration for asset acquisition

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock, net of offering costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from sale of common stock, net of offering costs

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercises of warrants

0

-

-

-

5

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock issuance under employee stock purchase plan

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on note payable

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

31,382

8,975

0

0

5,846

-

-

-

15,486

8,671

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Net proceeds from March 2015 financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,000

0

0

0

Proceeds from convertible loan notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,000

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,780

0

0

0

-

-

16,913

24,911

25,887

0

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-2,671

-

-

-

6,004

-579

3,758

1,818

-3,971

-3,659

-7,770

-7,207

-10,452

2,789

1,951

1,801

190

-13,774

4,927

5,165

15,716

19,493

0

0

0

Supplemental schedule of non-cash investing and financing activities:
Property and equipment included in accounts payable

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

1,858

2,807

9,970

11,665

10,278

0

0

0

-

-

-

0

-

-

-

-

Fair value of warrant liability upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,210

0

0

0

-

-

-

-

-

-

-

-

Unpaid offering costs

0

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrant liability upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Conversion of convertible loan notes and accrued interest to Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,316

0

0

0

Accretion of Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0